Resources

In your experience, what have most studies about CGM demonstrated?

- HbA1c is lower in CGM users regardless of age or type of insulin delivery.
- Patients using MDI + CGM have greater reductions in HbA1c than those using CSII + CGM.
- Reductions in glycemic variability and time spent in hypoglycemia are not significantly different between SAP and MDI/RT-CGM therapy groups.
- All of the above

Follow the link to see how you and your colleagues compare.

Which is not a side effect of SGLT-2 Inhibitors?

A. Kidney failure
B. Hyperkalemia
C. Ketoacidosis
D. Hypertension
E. Increased cholesterol levels
F. Serious urinary tract infections
G. Increased bladder cancer risk
H. Serious allergic reactions

Follow the link for the answer.

We recently had a new patient, 75 years of age, who has class I obesity and prediabetes, and has had hypothyroidism for over 25 years. She is very active and has purposely lost weight, about 6 pounds. She told me she has had hair loss over the years and has seen a specialist for this, but lately it's been worse. She takes spironolactone, biotin, and zinc for her hair loss. She wanted to know what she could do about her hair. She is taking 150 mcg levothyroxine and 5 mcg liothyronine.

Richard Bergenstal, MD is an endocrinologist in Minneapolis, Minnesota and is affiliated with Park Nicollet Methodist Hospital. He received his medical degree from University of Chicago Pritzker School of Medicine and has been in practice for more than 20 years. Dr. Bergenstal accepts several types of health insurance, listed below. He is one of 5 doctors at Park Nicollet Methodist Hospital who specialize in Endocrinology, Diabetes & Metabolism.

In this week's Homerun Slides,  we conclude this series with blinded versus unblinded CGM and CGM utilization.

Several studies, culminating in the large and definitive Diabetes Control and Complications Trial and the United Kingdom Prospective Diabetes Study have established that hyperglycemia is the major risk factor for microvascular diabetic complications. Chronic hyperglycemia also seems to be a significant and independent, albeit weaker risk factor for macrovascular disease. Other adverse consequences of hyperglycemia include an increased susceptibility to infections.

In this Exclusive Interview transcript, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston about emerging automated insulin delivery devices and a dual pathway approach for CGMS and medications.

In this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed during the AACE 2018 convention in Boston about emerging automated insulin delivery devices.

In part 1 of this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about emerging automated insulin delivery devices and the impact of CGM use on blood sugar management.

In part 2 of this Exclusive Interview, Richard Bergenstal talks with Diabetes in Control Publisher Steve Freed about the educational benefit from using CGM for type 2 diabetes.